Isolation of fully human antagonistic RON antibodies showing efficient block of downstream signaling and cell migration

Translational Oncology

Volumn 4, Issue 1, 2011, Pages 38-46

  Gunes, Zeynep ^a,b   Zucconi, Adriana ^a,b   Cioce, Mario ^a,c   Meola, Annalisa ^a,c   Pezzanera, Monica ^a,c   Acali, Stefano ^a,c   Zampaglione, Immacolata ^a,c   de Pratti, Valeria ^a,c   Bova, Luca ^a,d   Talamo, Fabio ^a,e   Demartis, Anna ^a,e   Monaci, Paolo ^a,e   la Monica, Nicola ^a,f   Ciliberto, Gennaro ^a,g   Vitelli, Alessandra ^a,h  

^a IRBM   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d Menarini Ricerche SpA   (Italy)

^e PHILIP MORRIS PRODUCTS S A   (Switzerland)

^f HYBRIDON INC   (United States)

^g UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^h Pomezia ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G10; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN G7; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RON; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL MIGRATION; MOUSE; NONHUMAN; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 79251579351     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.10211     Document Type: Article

References (43)

1. Clynes RA, Towers TL, Presta LG, and Ravetch JV (2000). Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6(4), 443-446.
2. Wang M-H, Yao H-P, and Zhou Y-Q (2006). Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers. Acta Pharmacol Sin 27(6), 641-650.
3. Camp ER, Liu W, Fan F, Yang A, Somcio R, and Ellis LE (2005). RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann Surg Oncol 12(4), 273-281.
4. Thomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penofiel MP, Hingorani SR, Tuveson DA, Waltz SE, and Lowy AM (2007). The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res 67(13), 6075-6082.
5. Ronsin C, Muscarelli F, Mattei MG, and Breatnach R (1993). A novel putative receptor protein tyrosine kinase of the met family. Oncogene 8, 1195-1202.
6. Xu X-M, Wang D, Shen Q, Chen Y-Q, and Wang M-H (2004). RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. Oncogene 23, 8464-8474.
7. Gaudino G, Follenzi A, Naldini L, Collesi C, Santoro M, Gallo KA, Godowski PJ, and Comoglio PM (1994). Ron is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J 13(15), 3524-3532.
8. Kolodkin AL, Matthes DJ, and Goodman CS (1993). The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules. Cell 75, 1389-1399.
9. Angeloni D, Danilkovitch-Miagkova A, Miagkov A, Leonard EJ, and Lerman MI (2004). The soluble Sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation. J Biol Chem 279(5), 3726-3732.
10. Gherardi E, Love CA, Esnouf RM, and Jones EY (2004). The Sema domain. Curr Opin Struct Biol 14, 669-678.
11. Chen Q, Seol D-W, Carr B, and Zarnegar R (1997). Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines. Hepatology 26(1), 59-66.
12. O'Toole JM, Rabenau KE, Burns K, Lu D, Mangalampalli V, Balderes P, Covino N, Bassi R, Prewett M, Gottfredsen KJ, et al. (2006). Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res 66(18), 9162-9170.
13. Maggiora P, Marchio S, Stella MC, Giai M, Belfiore A, De Bortoli M, Di Renzo MF, Costantino A, Sismondi P, and Comoglio PM (1998). Overexpression of the RON gene in human breast carcinoma. Oncogene 16, 2927-2933.
14. Zhou Y-Q, He C, Chen Y-Q, Wang D, and Wang M-H (2003). Altered expression of the RON receptor tyrosine kinase in primary human colorectal adeno-carcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene 22, 186-197.
15. Wang M-H, Lee W, Luo Y-L, Weis MT, and Yao H-P (2007). Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J Pathol 413(4), 402-411.
16. Danilkovitch A, Miller M, and Leonard EJ (1999). Interaction of macrophage-stimulating protein with its receptor. J Biol Chem 274(42), 29937-29943.
17. Wang M-H, Zhou Y-Q, and Chen Y-Q (2002). Macrophage-stimulating protein and RON tyrosine kinase: potential regulators of macrophage inflammatory activities. Scand J Immunol 56, 545-553.
18. Danilkovitch-Miagkova A (2003). Oncogenic signaling pathways activated by RON receptor tyrosine kinase. Curr Cancer Drug Targets 3, 31-40.
19. Danilkovitch-Miagkova A and Leonard EJ (2001). Cross-talk between RON receptor tyrosine kinase and other transmembrane receptors. Histol Histopathol 16, 623-631.
20. Chen Y-Q, Zhou Y-Q, Angeloni D, Kurtz AL, Qiang X-Z, and Wang M-H (2000). Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. Exp Cell Res 261, 229-238.
21. Thangsamy A, Rogge J, and Ammanamanchi S (2009). Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1α-mediated invasion of breast carcinoma cells. J Biol Chem 284, 14001-14010.
22. Danilkovitch-Miagkova A, Angeloni D, Skeel A, Donley S, Lerman M, and Leonard EJ (2000). Integrin-mediated RON growth factor receptor phosphor-ylation requires tyrosine kinase activity of both the receptor and c-Src. J Biol Chem 275(20), 14783-14786.
23. Wang D, Shen Q, Chen Y-Q, and Wang M-H (2004). Collaborative activities of macrophage-stimulating protein and transforming growth factor-β1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase. Oncogene 23, 1668-1680.
24. Follenzi A, Bakovic S, Gual P, Stella MC, Longati P, and Comoglio PM (2000). Cross-talk between the proto-oncogenes Met and Ron. Oncogene 19, 3041-3049.
25. Peace BE, Hill KJ, Degen SJF, and Waltz SE (2003). Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor. Exp Cell Res 289, 317-325.
26. Hsu P-Y, Liu H-S, Cheng H-L, Tzai T-S, Guo H-R, Ho C-L, and Chow N-H (2006). Collaboration of RON and epidermal growth factor receptor in human bladder carcinogenesis. J Urol 176, 2262-2267.
27. Maggiora P, Lorenzato A, Fracchioli S, Costa B, Castagnaro M, Arisio R, Katsaros D, Massobrio M, Comoglio PM, and Di Renzo MF (2003). The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res 288, 382-389.
28. Chen Y-Q, Zhou Y-Q, Fu L-H, Wang D, and Wang M-H (2002). Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase. Carcinogenesis 23(11), 1811-1819.
29. Zinser GM, Leonis MA, Toney K, Pathrose P, Thobe M, Kader SA, Peace BE, Beauman SR, Collins MH, and Waltz SE (2006). Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with β-catenin activation. Cancer Res 66(24), 11967-11974.
30. Kretschmann KL, Eyob H, Buys SS, and Welm AL (2010). The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression. Curr Drug Targets 11, 1157-1168.
31. Wang J, Rajput A, Kan JLC, Rose R, Liu X-Q, Kuropatwinski K, Hauser J, Beko A, Dominquez I, Sharratt EA, et al. (2009). Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma. J Biol Chem 284(16), 10912-10922.
32. Hegmans JP, Radosevic K, Voerman JS, Burgers JA, Hoogsteden HC, and Prins JB (2002). A model system for optimising the selection of membrane antigen-specific human antibodies on intact cells using phage antibody display technology. J Immunol Methods 262, 191-204.
33. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, and Johnson KS (1996). Human antibodies with sub-nanomolar affinities isolated from a large nonimmunized phage display library. Nat Biotechnol 14, 309-314.
34. Monaci P, Luzzago A, Santini C, De Pra A, Arcuri M, Magistri F, Bellini A, Ansuini H, Ambrosio M, Ammendola V, et al. (2008). Differential screening of phage-Ab libraries by oligonucleotide microarray technology. PLoS One 3, e1508.
35. Wahl RC, Costignan CJ, Batac JP, Chen K, Cam L, Courchesne PL, Patterson SD, Zhang K, and Pacifici RE (1997). Mutation of Cys672 allows recombi-nant expression of activable macrophage stimulating protein. J Biol Chem 272, 15053-15056.
36. Montero-Julian FA, Dauny I, Flavetta S, Ronsin C, Andre F, Xerri L, Wang M-H, Marvaldi J, Breathnach R, and Brailly H (1998). Characterization of two monoclonal antibodies against the RON tyrosine kinase receptor. Hybridoma 17, 541-551.
37. Feres KJ, Ischenko I, and Hayman MJ (2009). The RON receptor tyrosine ki-nase promotes MSP-independent cell spreading and survival in breast epithelial cells. Oncogene 15, 279-288.
38. Wang MH, Wang D, and Chen YQ (2003). Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis 24, 1291-1300.
39. Benvenuti S and Comoglio PM (2007). The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 213, 316-325.
40. Guin S, Yao H-P, and Wang M-H (2010). RON receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxicity. Mol Pharm 7(2), 386-397.
41. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, et al. (2003). A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cyto-reductive antitumor activity in vivo. Cancer 63, 7345-7355.
42. Camp ER, Yang A, Gray MJ, Fan F, Hamilton SR, Evans DB, Hooper AT, Pereira DS, Hicklin DJ, and Ellis LM (2007). Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target. Cancer 109(6), 1030-1039.
43. Conrotto P, Corso S, Gamberini S, Comoglio PM, and Giordano S (2004). Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene 23, 5131-5137.